Home    Back

Rvt-1401 340 mg/weekly    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia1

61. Autoimmune hemolytic anemia    [ 90 clinical trials,   72 drugs,   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways]
Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 90 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04253236
(ClinicalTrials.gov)		August 11, 202021/1/2020To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic AnemiaWarm Autoimmune Hemolytic AnemiaDrug: RVT-1401 680 mg/weekly;Drug: RVT-1401 340 mg/weeklyImmunovant Sciences GmbHNULLRecruiting18 YearsN/AAll16Phase 2United States;Israel;Korea, Republic of;Spain;Thailand;United Kingdom